Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 13, 2016 16:01 ET | Source: Revance Therapeutics, Inc

Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines

NEWARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
June 02, 2016 18:12 ET | Source: Revance Therapeutics, Inc

Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio

- Portfolio covers diverse and novel indications, compositions and formulations - - Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders- NEWARK, Calif., June...
May 31, 2016 16:05 ET | Source: Revance Therapeutics, Inc

Revance to Participate in Upcoming Investor Conferences

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
May 09, 2016 16:05 ET | Source: Revance Therapeutics, Inc

Revance Releases First Quarter 2016 Results

- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow’s Feet Lines –- Moves Phase 2 Dose-Escalating Trial for RT002 Injectable for Cervical Dystonia into Second Cohort - ...
April 25, 2016 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release First Quarter 2016 Financial Results Monday, May 9, 2016

NEWARK, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
March 14, 2016 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Expands Leadership Team, Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Development

NEWARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic...
March 05, 2016 13:45 ET | Source: Revance Therapeutics, Inc

Revance Announces Late-Breaking Podium Presentation of Positive 6-Month Duration Results for BELMONT Phase 2 Active Comparator Study of Injectable RT002 at the 74th Annual Meeting of the American Academy of Dermatology

- Findings confirm statistically significantly greater duration of effect for RT002 compared to BOTOX® Cosmetic - - 40U dose of RT002 planned to enter pivotal Phase 3 study in the second half of 2016...
March 02, 2016 16:05 ET | Source: Revance Therapeutics, Inc

Revance Releases Fourth Quarter and Full Year 2015 Results

- Announces 2016 Outlook -- On Track to Achieve Multiple Clinical Development Milestones in 2016 - NEWARK, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC),...
February 23, 2016 16:05 ET | Source: Revance Therapeutics, Inc

Revance to Participate in Upcoming Investor Conferences

NEWARK, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
February 17, 2016 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release Fourth Quarter and Full Year 2015 Financial Results Wednesday, March 2, 2016

NEWARK, Calif., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...